• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to secondary sidebar
  • Skip to footer

  • Opinion
  • Health IT
    • Behavioral Health
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Patient Engagement
    • Population Health Management
    • Revenue Cycle Management
    • Social Determinants of Health
  • Digital Health
    • AI
    • Blockchain
    • Precision Medicine
    • Telehealth
    • Wearables
  • Life Sciences
  • Investments
  • M&A
  • Value-based Care
    • Accountable Care (ACOs)
    • Medicare Advantage

Helix Launches Clinico-Genomic Datasets to Accelerate Precision Medicine Drug Discovery

by Fred Pennic 06/07/2024 Leave a Comment

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

What You Should Know: 

– Helix, a leader in population genomics, is launching new datasets designed to empower life science companies in developing precision medicine therapies. 

– These comprehensive datasets, built through collaborations with various health systems, provide researchers with a rich resource for drug discovery and development across multiple disease areas.

Unveiling the Power of Clinico-Genomic Data

The datasets offer a unique combination of longitudinal clinical data and genomic information. This includes extensive medical records spanning a patient’s healthcare journey, along with their genetic makeup. The data covers a wide range of therapeutic areas, including:

  • Cardiovascular diseases
  • Immunological and inflammatory conditions
  • Metabolic disorders

Precision Cohorts for Targeted Research

Helix’s approach leverages “precision cohorts,” meticulously curated groups of patients with specific characteristics. These cohorts combine longitudinal clinical data, such as diagnoses, procedures, lab results, and medications, with genetic information obtained through Helix’s proprietary Exome+® sequencing technology. This comprehensive data is available for over 125,000 consented patients across the US, allowing researchers to target specific patient populations for their studies.

Real-World Data for Real-World Solutions

The datasets are further enhanced by regular updates, ensuring researchers have access to the latest clinical information. This includes structured data from electronic health records (EHRs), providing a detailed picture of a patient’s health. For instance, the Cardiometabolic cohort offers data for over 50,000 patients with cardiovascular disease. This includes patient vitals, demographics, and key lab results like cholesterol and blood sugar levels. Critically, all of this clinical data is linked to a patient’s exome sequencing data, allowing researchers to identify genetic variations that influence disease risk and treatment response.

“Life science researchers can utilize Helix’s diverse clinico-genomic cohorts to better understand genetic factors associated with disease progression and clinical outcomes, as well as validating therapeutic candidates of interest,” said Hylton Kalvaria, Chief Commercial Officer of Helix. “Organizations can also rapidly identify targeted patient populations based on specific genetic and phenotypic criteria to optimize discovery and clinical development.”

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

Tagged With: dataset, Drug Discovery, Precision Medicine

Tap Native

Get in-depth healthcare technology analysis and commentary delivered straight to your email weekly

Reader Interactions

Primary Sidebar

Subscribe to HIT Consultant

Latest insightful articles delivered straight to your inbox weekly.

Submit a Tip or Pitch

Featured Interview

Reach7 Diabetes Studios Founder Chun Yong on Reimagining Chronic Care with a Concierge Medical Model

Most-Read

Advancing Diabetes Care: Combating Burnout and Harnessing Technology

Advancing Diabetes Care: Combating Burnout and Harnessing Technology

White House Event Unveils CMS Health Tech Ecosystem Initiative

White House Event Unveils CMS Health Tech Ecosystem Initiative

Meaningful Use Penalties_Meaningful Use_Partial Code Free_Senators Urge CMS to Establish Clear Metrics for ICD-10 Testing

CMS Finalizes TEAM Model: A New Era of Value-Based Surgical Care

HHS Finalizes HTI-4 Rule: Prior Authorization & E-Prescribing Interoperability

HHS Finalizes HTI-4 Rule: Prior Authorization & E-Prescribing Interoperability

Digital Health Faces Q2'25 Pullback: Funding Falls to 5-Year Low, But AI Dominates and $1B+ IPOs Emerge

Healthcare Investment Shifts in 1H 2025: AI Remains a Bright Spot Amidst Fundraising Decline

Digital Health Faces Q2'25 Pullback: Funding Falls to 5-Year Low

Digital Health Faces Q2’25 Pullback: Funding Falls to 5-Year Low

Beyond the Hype: Building AI Systems in Healthcare Where Hallucinations Are Not an Option

Beyond the Hype: Building AI Systems in Healthcare Where Hallucinations Are Not an Option

Health IT Sector Navigates Policy Turbulence with Resilient M&A

Health IT’s New Chapter: IPOs Return, Resilient M&A, Valuations Rise in 1H 2025

PwC Report: US Medical Cost Trend to Remain Elevated at 8.5% in 2026

PwC Report: US Medical Cost Trend to Remain Elevated at 8.5% in 2026

Philips Launches ECG AI Marketplace, Partnering with Anumana to Enhance Cardiac Care with AI-Powered Diagnostics

Philips Launches ECG AI Marketplace, Partnering with Anumana to Enhance Cardiac Care with AI-Powered Diagnostics

Secondary Sidebar

Footer

Company

  • About Us
  • Advertise with Us
  • Reprints and Permissions
  • Submit An Op-Ed
  • Contact
  • Subscribe

Editorial Coverage

  • Opinion
  • Health IT
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Population Health Management
    • Revenue Cycle Management
  • Digital Health
    • Artificial Intelligence
    • Blockchain Tech
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • Value-Based Care
    • Accountable Care
    • Medicare Advantage

Connect

Subscribe to HIT Consultant Media

Latest insightful articles delivered straight to your inbox weekly

Copyright © 2025. HIT Consultant Media. All Rights Reserved. Privacy Policy |